Patients with AML or myelodysplastic syndrome who relapse after allo-SCT have a poor prognosis. In the search for novel treatment strategies for these patients, we conducted a multicenter retrospective analysis and identified 22 patients treated with the DNA-methylation inhibitor 5-azacytidine (5-Aza). Patients received a median number of two cycles 5-Aza (range 1-8) at a dose of 100 mg/m 2 over 5 days following relapse. Eighteen patients (82%) also received a median number of two donor lymphocyte infusions (DLI, range 1-5). Sixteen patients (72%) responded to 5-Aza treatment and five patients (23%) achieved a CR. 5-Aza-induced CR lasted for 433 days (median, range 114-769). Median survival and the estimated 2-year survival rate were 144 days and 23%, respectively. Acute GVHD after DLI was seen in six patients (33%) and four of these patients developed chronic GVHD of the skin. There were no treatmentrelated deaths. Patients who achieved halving of leukocyte counts after the first 5-Aza cycle had a superior median survival of 802 days compared with 135 days (P ¼ 0.0025) in all other patients. On univariate analysis, the achievement of this halving of leukocyte counts was identified as a significant predictor of survival.
Introduction
Patients with myelodysplastic syndrome (MDS) or AML who relapse after allo-SCT have an abysmal outcome. [1] [2] [3] Current treatment options involve a second allogeneic graft, conventional salvage chemotherapy or donor lymphocyte infusions (DLI). 2, 4 The latter one is practicable for most patients, but is often unsuccessful in those with unfavorable cytogenetics, with more than one relapse in the past and/or in those not in remission at the time of DLI. 2 However, patients who suffer a relapse after allogeneic SCT usually belong to the above-mentioned unfavorable groups and induction of a CR in these patients before DLI is challenging. [1] [2] [3] 5 Hence, there is a need for novel, non-toxic and efficient therapeutic strategies for the treatment of these patients. The pyrimidine analogon 5-Azacytidine (5-Aza) exerts anti-proliferative effects because of hypomethylation of DNA and direct cytotoxicity on malignant hematopoietic cells. 6, 7 In addition, 5-Aza can induce remissions in patients with AML or MDS who are refractory to conventional chemotherapy. [8] [9] [10] [11] We performed a retrospective analysis of 22 patients to evaluate the capability of 5-Aza to reinduce remissions in patients with AML or MDS who relapse after allo-SCT. Furthermore, we looked for factors predicting survival in these patients.
Patients and methods

Data collection
Centers participating in the German Cooperative Group for hematopoietic SCT were asked about their experience with 5-Aza for the treatment of patients with AML or MDS who relapse after allo-SCT. We received reports on 22 patients treated between January 2005 and August 2008 at the University Hospitals of Dresden, Duesseldorf and Hamburg. Written informed consent was obtained from all patients.
Patient and transplant characteristics
Patient characteristics are summarized in Table 1 . The median age of the 22 patients analyzed was 50 years (range 28-69 years), of which 10 were male patients (45%). Thirteen patients (59%) had AML, four (18%) had MDS, four (18%) had secondary AML after MDS and one patient (5%) had a Philadelphia chromosome-negative myeloproliferative syndrome. Twenty patients (91%) received myeloablative and two patients (9%) received nonmyeloablative conditioning for allo-SCT. Ten patients (45%) received an allograft from a matched sibling donor and 12 patients (55%) from a matched unrelated donor. Graft sources were PBSCs for 21 patients (96%) and BM for one patient (4%). Sixteen patients had active disease (73%) before allogeneic SCT, whereas six patients (27%) were in CR, although three (50%) out of these six patients were stratified as high risk because of treatment-related MDS (t-MDS) or secondary AML after MDS.
All patients achieved a CR after allogeneic SCT and patients' median chimerism 4 weeks after SCT was 100% (range 91.4-100%). Median time to relapse after SCT was day þ 103 (range 48-708 days). Following relapse all patients received s. Relapse and response evaluation Relapse after allo-SCT was defined as recurrence of BM blasts 45% and loss of donor chimerism. Treatment response was defined as follows: A CR was defined as less than 5% BM blasts and normalization of peripheral blood counts for at least 4 weeks. PR was defined as a reduction of BM blasts by at least 50%, which lasted for nearly 4 weeks. Stable disease was defined as the absence of disease progression for at least 4 weeks.
Statistical methods
Treatment response, GVHD onset and overall survival were calculated from the first day of 5-Azacytidine treatment to the respective event. Death from whatever cause was counted as an event in case of overall survival. The time-to-event curve was estimated according to the method of Kaplan and Meier. The patient who received a second allograft was censored at the first day of conditioning therapy for survival analysis. The equality of survival between different groups was tested using the log-rank test. Univariate prognostic factor analysis was calculated by linear regression. All statistical analyses were performed using STATA 10.1 (StataCorp LP, College Station, TX, USA).
Results
Treatment response and survival
Looking at the entire group of 22 patients, 16 (72%) responded to treatment with 5-Aza, including five CR, four PR and six disease stabilizations, and one patient showed a hematological and cytogenetic improvement. None of the patients, including those who achieved a CR, received any additional salvage therapy before 5-Azacytidine treatment. With regard to overall survival, the estimated 2-year 5-Aza for treatment of relapse after allo-SCT A Czibere et al survival rate and the median survival rate were 23% and 144 days, respectively ( Figure 1 ). Currently, there are four patients alive: one patient in CR on day þ 862, one patient on day þ 824 who relapsed again on day þ 821 and currently receives palliative care, one patient who achieved a PR and received a second allograft on day þ 90 and one patient on day þ 443 who initially relapsed with refractory cytopenia and multilineage dysplasia and showed a temporary hematological and cytogenetic improvement following treatment with 5-Aza and DLI. 5-Aza-induced CR lasted for 433 days (median, range 114-769), though three of the five patients who achieved a CR relapsed again at the extramedullary sites on day þ 433 (heart), on day þ 384 (lymph nodes) and on day þ 114 (CNS) while maintaining hematological remissions. The first patient responded again to 5-Aza treatment and maintained a PR for another 361 days and died on day þ 802 after the initial 5-Aza treatment because of progressive disease. The second patient received additional chemotherapy and died on day þ 506, whereas the third patient died 9 days after the diagnosis of a CNS relapse. Looking at the common characteristics of the five patients who achieved a CR, we found that all five patients achieved a reduction of their peripheral blood leukocyte counts by at least 50% after the first 5-Aza treatment cycle, which lasted until the second 5-Aza course was administered 28 days later. Within the entire group of patients, a total number of 10 out of 22 patients achieved such halving of leukocyte counts after the first 5-Aza treatment cycle. When comparing the cumulative survival of these patients with the cumulative survival of those who did not achieve a sustained halving of leukocyte counts, we found a significantly superior median survival of 802 days compared with 135 days (P ¼ 0.0025) in all the others.
GVHD
Six patients (33%) developed acute GVHD symptoms after DLI with a median onset time of 138 days (range 43-317) after the first DLI. Median time between the first 5-Aza cycle and first DLI was 35 days (range 18-38 days). Before GVHD was diagnosed in these patients, they received a median number of three DLIs (range 2-5) and four 5-Aza courses (range 2-6). The skin was affected in all six patients, whereas three patients also had hepatic GVHD. All patients responded to GVHD treatment and four patients retained limited chronic cutaneous GVHD, which was associated with prolonged CR. It is noted that five of the six patients who had GVHD were already in CR at the time of GVHD onset. All five patients who achieved a lasting CR achieved a blast clearance due to 5-Aza treatment before the first DLI was given. None of the patients who received the DLI with residual disease activity achieved an ongoing CR. The remaining patients with GVHD had reached a PR and received a second allograft on day þ 90 after the initial relapse. There were no GVHDrelated deaths and the four patients who did not receive DLI died from progressive disease before DLI could be given.
5-Azacytidine-related toxicities
There were no treatment-related deaths and toxicities were manageable and limited to the hematopoietic system and local reactions at the injection site. According to the WHO classification hematopoietic toxicity was as follows: Eight patients had grade 0, five had grade 1, two had grade 2, zero had grade 3 and seven patients had grade 4 toxicity. Of the 16 patients who responded to treatment with 5-Azacytidine, six patients needed hospitalization due to infections as a cause of neutropenia. All of these six patients still had peripheral and/or BM blast cells at the time of hospitalization. The remaining 10 patients, including the five patients who achieved a CR, could be managed on an outpatient basis during the entire time of treatment.
Risk factors for survival following salvage therapy with 5-Azacytidine
In a univariate analysis, achievement of a reduction of peripheral leukocyte counts by at least 50%, which lasted until the second 5-Aza treatment cycle was given (28-day intervals), was identified as an independent significant predictor of survival for the 22 patients examined here (P ¼ 0.001).
Discussion
Several attempts have been made to improve the survival of AML or MDS patients with a relapse after allogeneic SCT with, so far, unsatisfactory results. Current treatment strategies include palliative care, conventional chemotherapy, a second allo-SCT and/or DLI. [2] [3] [4] As prospective multicenter trials for patients with relapse after allo-SCT are lacking and difficult to perform, no standard care regimen has been defined to date. In a recent EBMT-wide analysis on 399 patients with AML in first hematological relapse, the addition of DLI to any salvage therapy has been shown to be favorable in terms of overall survival, especially for those patients who are already in CR at the time of DLI. 2 However, the induction of a CR before DLI Unadjusted survival of all 22 patients with AML or MDS who relapsed after allo-SCT and were treated with 5-Azacytidine. Estimated overall survival after 2 years was 23% with a median overall survival of 144 days.
5-Aza for treatment of relapse after allo-SCT A Czibere et al is challenging in these patients. Generally, only low-toxic treatment regimens are feasible due to the cumulative toxicity of the preceding allo-SCT, particularly for those patients who suffer their relapse within the first 6 months after myeloablative allo-SCT. The DNA-methylation inhibitor 5-Aza is currently under investigation for the treatment of patients with imminent relapse as defined by a decreased chimerism in peripheral CD34 þ cells. 12 Patients received s.c. 5-Aza at a dose of 75 mg/m 2 over 7 days every 28 days but no DLI and first results from this phase-II trial are promising and show a good tolerability and efficacy of this treatment strategy to prevent full relapse in these patients. 12 On the basis of the preliminary data and the fact that 5-Aza is effective in patients with refractory or relapsed AML without the toxic burden of conventional salvage regimens, 5-Aza is a promising candidate to reinduce hematological remissions in patients with AML or MDS who relapse after allo-SCT before DLI.
Here, in this retrospective analysis, we show that outpatient treatment with 5-Aza in addition to DLI can reinduce durable remissions in patients with AML or MDS who have their primary relapse after allo-SCT. None of the 22 patients examined here died from treatment-related mortality. The single cause of death was progressive disease, supporting the safety of 5-Aza treatment in this clinically challenging situation. This observation is strengthened by the fact, that the only grade III-IV toxicity observed was cytopenia, whereas it was obviously difficult to distinguish between treatment-related toxic cytopenia and cytopenia caused by the relapse itself. The 2-year overall survival rate and the median survival time observed in our analysis were superior to most studies published previously. [13] [14] [15] [16] The initial response rate to 5-Aza treatment was remarkably high, but in all cases where no CR was achieved, response did not last. A major problem remaining, is the occurrence of extramedullary relapse in patients who maintain a hematological remission with a full donor chimerism and a reconstituted donor immune system. All the three patients examined here who suffered extramedullary relapse did so in complete hematological remission. It is unclear, whether these extramedullary relapses arose from a new clone or from quiescent cells, which settled down in the heart muscle, CNS or lymph nodes during the stage of peripheral blast circulation. Another interesting aspect is how these cells manage to circumvent the GVL effect of the reconstituted donor immune system. Nonetheless, treatment of extramedullary relapse is extremely difficult and limited to palliative care in most of the cases. The current focus should clearly be the prevention of extramedullary relapse. An appropriate strategy might be a continued low-dose maintenance therapy with 5-Azacytidine in patients who achieved a hematological remission. Surprisingly, different prognostic groups could be distinguished according to the patients' immediate response to the first 5-Aza treatment cycle as defined by a reduction of the peripheral leukocyte counts of at least 50% after the first treatment cycle which had to last 28 days before the second treatment cycle was given. In a univariate linear regression analysis, this halving of leukocyte counts was a significant predictor of survival (P ¼ 0.001), whereas other variables such as the duration of the remission after allografting (P ¼ 0.348), remission status before the allo-SCT (P ¼ 0.632), cytogenetics before allo-SCT (P ¼ 0.474), more than 20% BM blasts at the time of relapse (P ¼ 0.311), an age 455 years (P ¼ 0.949), female gender (P ¼ 0275) or elevated serum LDH levels (P ¼ 0.152) did not influence survival substantially in these patients. However, the observation of an immediate response to 5-Aza treatment differs from previous reports in patients with MDS, in which responses to treatment were also seen after three or more treatment cycles. 17 Given the late onset of GVHD and the relatively high number of DLIs necessary to induce GVHD, it could be assumed that the treatment with 5-Aza has an influence on the donor immune system. In this regard, previous reports showed induction of killer Ig-like receptors 18 in NK cells following treatment with DNA-demethylating agents. 19 It is well established that NK cells are involved in the specific recognition of leukemic target cells and are able to enhance the GVL effect. [20] [21] [22] [23] Thus, we suppose an interplay between 5-Aza and DLI, in which treatment with 5-Aza first leads to a reduction of the leukemic burden by an anti-proliferative effect on the leukemic target cells and then modulates the donor T-and NK-cell compartment, thereby paving the way for a reconstitution of the collapsed GVL effect. This might be able to consolidate 5-Aza-induced CR.
